About: Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin E2, method of production thereof and use thereof

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin E2, method of production thereof and use thereof Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20141111&DB=EPODOC&locale=en_EP&CC=US&NR=8883798B2&KC=B2&ND=4
Description	The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided. The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided. (en)
Title	Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin E2, method of production thereof and use thereof Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin E2, method of production thereof and use thereof (en)
skos:prefLabel	Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin E2, method of production thereof and use thereof Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin E2, method of production thereof and use thereof (en)
skos:notation	RIV/68378041:_____/14:00438200!RIV15-AV0-68378041
http://linked.open...avai/riv/aktivita	I
http://linked.open...avai/riv/aktivity	I
http://linked.open...cisloPatentuVzoru	US8883798
http://linked.open...eleniPatentuVzoru	2014-11-11 (xsd:date)
http://linked.open...vai/riv/dodaniDat	2015
http://linked.open...aciTvurceVysledku	Zídek, Zdeněk Kmoníčková, Eva
http://linked.open.../riv/druhVysledku	P - Patent
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Ústav experimentální medicíny AV ČR, v. v. i.
http://linked.open...dnocenehoVysledku	40956
http://linked.open...ai/riv/idVysledku	RIV/68378041:_____/14:00438200
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	pyrimidine compounds; prostaglandin E2; nitric oxide (en)
http://linked.open.../riv/klicoveSlovo	nitric oxide prostaglandin E2 pyrimidine compounds
http://linked.open...ontrolniKodProRIV	[6AF296CAF669]
http://linked.open.../licencniPoplatek	A - Poskytovatel licence na výsledek požaduje licenční poplatek
http://linked.open...ydaniPatentuVzoru	Alexandria
http://linked.open...atelePatentuVzoru	United States Patent and Trademark Office (USPTO)
http://linked.open...in/vavai/riv/obor	FR
http://linked.open...ichTvurcuVysledku	2 (xsd:int)
http://linked.open...cetTvurcuVysledku	5 (xsd:int)
http://linked.open...UplatneniVysledku	2014
http://linked.open...ydaniPatentuVzoru	US - Spojené státy americké
http://linked.open...iv/tvurceVysledku	Holý, Antonín Janeba, Zlatko Jansa, Petr Zídek, Zdeněk Kmoníčková, Eva
http://linked.open...mniOchranaPatentu	B - USTPO (Úřad pro patenty a ochranné známky USA)
http://linked.open...avai/riv/vlastnik	Ústav organické chemie a biochemie AV ČR, v. v. i. - Ústav experimentální medicíny AV ČR, v. v. i
http://linked.open...itiJinymSubjektem	A - Nabytí licence je nutné vždy
http://linked.open...uzitiPatentuVzoru	A - Pouze udělený nebo využívaný pouze vlastníkem
http://linked.open...stnikPatentuVzoru	Ústav organické chemie a biochemie AV ČR, v. v. i. - Ústav experimentální medicíny AV ČR, v. v. i

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software